Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
|Slideshows|December 11, 2019
New COPD Drugs: 2019 in Review
Author(s)By Leo Robert
FDA 2019 approvals for COPD treatment included a cryotherapy spray and other novel & breakthrough therapies. Updates at-a-glance, here.
Advertisement
For primary care and other clinicians who treat COPD, 2019 was a year of innovation.FDA approved the first once-daily nebulized bronchodilator; a Breakthrough Device that delivers cryotherapy; and, the first generic of Advair Diskus. In other developments, aspirin was found to reduce COPD mortality and macrolides to reduce frequency of acute exacerbations.Scroll through the slides below for short summaries of these and other news important to optimal management of COPD.
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
Advertisement
Advertisement
Trending on Patient Care Online
1
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
2
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
5